The European Heart Failure (HF) Survey was developed by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) to map HF management resources, reimbursement of drugs/devices for HF treatment, and structure and activities of HF professional and patient organizations.

Many patients with heart failure (HF) are iron-deficient. Intravenous (IV) iron therapy improves symptoms and reduces hospitalizations for HF. Several mechanisms have been proposed, including myocardial iron repletion. However, it is unknown if serum iron markers predict the extent of this repletion. To address this question, data from two clinical studies that evaluated changes in myocardial iron

Click on the article title to read more.

AimsCentral venous pressure (CVP) is an important variable in assessing heart failure (HF) patients. However, invasive CVP measurement using right heart catheterization is associated with potential complications, and accurate measurement requires careful attention to technique. In this multicentre pilot study, we aimed to evaluate whether non‐invasively measured liver stiffness can be used to assess

A better understanding of additional mechanisms of heart failure (HF) progression may allow a different and more complete phenotyping of the disease and identification of novel therapeutic targets. Persistent latent myocardial inflammation/immune activation in HF may represent an attempt to restore tissue homeostasis in the failing heart, where cardiomyocytes and immune cells undergo metabolic reprogramming

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

AimsThe safety and efficacy of heart failure (HF)‐directed medical therapy among patients who might be considered for further diagnostic evaluation to rule out transthyretin amyloid cardiomyopathy (ATTR‐CM) is largely unknown.Methods and resultsWe applied a previously validated ATTR‐CM screening score in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and assessed

A recently published clinical consensus statement suggested that serial measurements of left ventricular ejection fraction (LVEF) should be done routinely for patients with heart failure, to assess disease progression and response to treatment.1 These recommendations were applied regardless of left ventricular phenotype. However, there is little evidence to suggest that serial assessment of LVEF will

AimsAlthough functional recovery of the failing heart with left ventricular assist device (LVAD) unloading can occur, the underpinning mechanism is unclear. We aimed to characterize the effect of myocardial biochemical effect of LVAD support in vivo and in vitro.Methods and resultsWe performed targeted metabolomics and lipidomics on transcardiac (arterial and coronary sinus) blood samples collected

Click on the article title to read more.

AimsThe Heart Failure Association (HFA) of the European Society of Cardiology (ESC), together with the National Heart Failure Societies (NHFS), designed the European Heart Failure (HF) Survey with an aim of assessing contemporary HF epidemiology, management resources, availability and reimbursement of guideline‐directed medications and devices, and structure of professional and patient organizations

AimsRandomized clinical trials (RCTs) that inform international clinical practice guidelines should adequately represent regions burdened with disease. We aimed to assess the geographic representativeness of pivotal heart failure (HF) RCTs using two methodological approaches.Methods and resultsWe assessed the global geographic distribution of HF cases using the Global Burden of Disease 2021 dataset

Click on the article title to read more.

Click on the article title to read more.

AimsPrevious analyses of the relationship between blood pressure (BP) and heart failure (HF) outcomes have primarily used baseline values rather than longitudinal measurements. We aimed to elucidate associations between longitudinal BP and clinical outcomes in patients with HF with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), and preserved ejection fraction (HFpEF)

Sudden cardiac death is a catastrophic event, making its prevention important. However, patient selection for primary prevention remains controversial. We report two cases of cardiac conduction disorder initially treated with permanent pacemaker implantation. Genetic testing later revealed novel pathogenic variants in LMNA, leading to an upgrade to implantable cardioverter‐defibrillator for primary

AimsOveractivity of the sympathetic nervous system is a common underlying mechanism in development and progression of several heart failure with preserved ejection fraction (HFpEF) comorbidities. Decreasing renal sympathetic nerve activity using catheter‐based renal denervation (RDN) systems have shown efficacy in treating resistant hypertension and cardiac dysfunction in heart failure with reduced

AimsIn the PIVOTAL trial, a proactive high‐dose regimen of intravenous iron sucrose, compared to a lower‐dose reactive regimen, reduced the risk of first and recurrent events of the primary endpoint in haemodialysis patients. We present the various approaches of recurrent event analyses for the primary endpoint and for the composite of cardiovascular (CV) death or heart failure hospitalization and

AimsIn clinical practice, simplifying the number of medication titration steps while maintaining safety may improve the likelihood of patients with heart failure (HF) achieving target doses of guideline‐directed medical therapy (GDMT). The VELOCITY study examined whether removing the 2.5 mg initiation step for vericiguat, and instead initiating therapy at 5 mg daily, would be safe and well‐tolerated

Anaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin–angiotensin system blockers reduce haemoglobin, little is known about the effect of mineralocorticoid receptor antagonists on haemoglobin and in patients with anaemia. We evaluated the effects of finerenone according to anaemia status in patients

AimsN‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations serve as markers of prognosis and therapeutic response in patients with heart failure (HF). The effect of the non‐steroidal mineralocorticoid receptor antagonist finerenone on NT‐proBNP in patients with HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is currently unknown.Methods and resultsThe FINEARTS‐HF

Click on the article title to read more.

We thank the authors for acknowledging our work. The diagnosis of previously unknown diabetes and pre-diabetes was based on only one measurement of glycated haemoglobin and not at least two measurements or supplementary analyses of non-fasting glucose, fasting glucose, and oral glucose tolerance, as recommended. Therefore, it is possible that some patients might have been recategorized. However, we

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Click on the article title to read more.

Heart transplantation remains the gold standard for treatment of most patients with advanced heart failure (HF), but despite improvements of organ recovery and utilization, donor heart scarcity remains a critically limiting factor. Detailed heart allocation systems (HASs) are in place to ensure use of organs for appropriate candidates, In Europe multiple, different HASs have evolved in different countries

Obesity and heart failure (HF) represent two growing pandemics. In the general population, obesity affects one in eight adults and is linked with an increased risk for HF. Obesity is even more common in patients with HF, where it complicates the diagnosis of HF and is linked with worse symptoms and impaired exercise capacity. Over the past few years, new evidence on the mechanisms linking obesity with

Introduction Tricuspid regurgitation (TR) is a major health burden being associated with substantial morbidity, mortality and quality of life (QoL) impairment.1 Advancements in transcatheter tricuspid valve interventions (TTVI) have significantly changed the landscape of tricuspid valve (TV) disease enabling treatment of elderly patients at advanced or prohibitive surgical risk. TV transcatheter edge-to-edge

AimsThermoregulation is a fundamental aspect of mammalian homeostasis. Skin blood flow has a key role to play in thermoregulation. Heart failure (HF) can disrupt thermoregulation. Infrared thermography (IRT) offers a non‐invasive method to map skin temperature (Ts). The aim of this study was to investigate the relationships between IRT‐assessed thermoregulation, circulatory volume, and exercise in

Click on the article title to read more.

Click on the article title to read more.

Episodes of worsening heart failure (HF) are a major cause of unplanned hospitalizations. Their onset is usually preceded by an early increase in intracardiac pressures with subsequent worsening of symptoms due to congestion. Implantable devices allowing daily remote pulmonary artery pressure (PAP) monitoring are useful to identify early haemodynamic changes so that medical therapy can be adjusted